Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24745145 | 1.00 | HSD11B1 (0.45) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL30117192 | 1.00 | HSD11B1 (0.45) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL19415337 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL27042347 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL30722926 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL34473728 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL15366822 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL15366820 | 0.87 | HSD11B1 (0.44) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL12144704 | 0.85 | HSD11B1 (0.47) | HSD11B1NR1H2CCR2F13A1TGM2 | |
| SCHEMBL19294001 | 0.85 | HSD11B1 (0.47) | HSD11B1NR1H2CCR2F13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| US-7101890-B2 | Benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2006-09-05 | — | — | US | disclosed |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | SANOCHEMIA LTD. (MT) | 2004-04-08 | — | — | US | disclosed |
| US-6638925-B2 | In particular benzofuro(3a,3,2,ef)(2)benzazepin; treatment of Alzheimer's disease and related dementia conditions, Langdon-Down syndrome | SANOCHEMIA LTD. (MT) | 2003-10-28 | — | — | US | disclosed |
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | SANOCHEMIA LTD. (MT) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092700-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME AND THEIR USE TO PREPARE MEDICAMENTS | PSEN2, BACE2, BACE1 | HSD11B1 549/4885NR1H2 1041/4885CCR2 4757/4885 |
| US-20040067974-A1 | New benzazepine derivatives, drugs containing these and use of the same for producing drugs | BACE2, PSEN2, BACE1 | HSD11B1 484/4885NR1H2 842/4885CCR2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.